Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • China rebukes west over military moves after close call in Taiwan Strait
    • India blames train crash on signal failure as death toll nears 300
    • Three Israeli soldiers shot dead on Egyptian border
    • Train crash in India kills more than 260 people
    • Erdoğan signals economic shift for Turkey as he revamps cabinet
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Somerset’s ‘smelly town’ sets its sights on UK’s biggest gigafactory for revival
    • Boris Johnson at risk of losing Covid inquiry legal funding, Whitehall warns
    • Why Britain’s households should expect energy bills to remain high
    • Siemens and Microsoft give last-minute backing to CBI
    • UK medical cannabis group woos patients to buy into the business
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Boiler makers up in arms over UK heat pump targets
    • UBS considers delaying results after Credit Suisse rescue deal
    • AstraZeneca defies geopolitics to bet on China
    • ‘This is not just channel Farage’: GB News boss positions his station as ‘mainstream’
    • Asda’s owners recycle proceeds of earlier deal to fund EG takeover
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Saudi Arabia’s ‘prickly prince’ of oil bristles as crude price slides
    • Saudi Arabia seeks to boost oil price with output cut of 1mn barrels a day
    • Japan inflation will drive savers back to the stock market, says exchange chief
    • Handful of tech stocks drive diverging measures of S&P 500 performance
    • Orlen: is Poland’s energy giant a tool of the government?
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The frictionless life goes on
    • Management 101: don’t drain a reservoir to find your phone
    • Europe’s new success stories are built on high luxury, not high tech
    • Ukraine’s rapid reconstruction will be in Europe’s own interest
    • AI has given Palantir its mystique back
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Can a virtual PA turbocharge your career?
    • The dismal truth about email
    • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Why motorcycle gangs will end with a whimper, not a rev
    • Cristiano Ronaldo vs Lionel Messi: who was the greatest footballer?
    • Sci-fi writer Ted Chiang: ‘The machines we have now are not conscious’
    • The American luxury lifestyle brand storming the Cotswolds
    • Trump or not, US meltdown could be inevitable
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Jamie Smyth

US Pharmaceutical Correspondent

Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Sunday, 4 June, 2023
    Supply chains
    US cancer drug shortage forces doctors to ration life-saving treatments

    Healthcare groups call for reforms to pharma supply chains as up to half a million patients could be affected

  • Friday, 2 June, 2023
    Health sector
    More than 400 Grail patients incorrectly told they may have cancer

    Error prompts life assurance customers to pause or review relationship with early detection biotech

  • Wednesday, 31 May, 2023
    News in-depthUS opioid epidemic
    ‘People rot from the inside out’: lethal xylazine deepens the US drug crisis

    Cartels are cutting fentanyl with the cheap sedative, driving a surge in overdoses in cities such as Philadelphia

  • Wednesday, 31 May, 2023
    Behind the Money podcast35 min listen
    Best Of: Inside Johnson & Johnson’s bankruptcy two-step

    Is this legal manoeuvre setting a precedent for corporations to evade accountability in America?

  • Tuesday, 30 May, 2023
    US opioid epidemic
    Purdue Pharma allowed to shield Sackler owners from opioid lawsuits

    Appeals court says some liability releases are ‘appropriate’ under US bankruptcy law

  • Saturday, 27 May, 2023
    Illumina Inc
    Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture

    World’s biggest gene sequencing company rejects EU’s fast- track application

  • Thursday, 25 May, 2023
    Illumina Inc
    Illumina chair ousted in proxy battle with Carl Icahn

    Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years

  • Wednesday, 24 May, 2023
    Abbott Laboratories
    Infant formula producers probed by FTC over bids for contracts

    Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families

  • Wednesday, 24 May, 2023
    InterviewIllumina Inc
    Illumina can survive loss of chair and CEO, says board director

    Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn

  • Wednesday, 17 May, 2023
    Mergers & Acquisitions
    M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns

    Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal

  • Wednesday, 17 May, 2023
    Amgen Inc
    Regeneron boss backs attempt to block $28bn Amgen acquisition

    Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics

  • Wednesday, 17 May, 2023
    The Big Read
    Quick blood tests to spot cancer: will they help or harm patients?

    Investors are pouring billions into companies claiming they can analyse DNA to find the disease early. But some scientists question if they really work

  • Sunday, 14 May, 2023
    Novavax Inc
    Cash-strapped Novavax urges governments to honour Covid jab deals

    US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic

  • Wednesday, 10 May, 2023
    Illumina Inc
    Glass Lewis backs Carl Icahn’s push to oust Illumina’s chief and chair

    Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail

  • Monday, 8 May, 2023
    Dementia
    Two Alzheimer’s drugs offer hope to patients after decades of waiting

    In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

  • Thursday, 4 May, 2023
    Johnson & Johnson Co Inc
    J&J consumer arm’s shares jump in biggest US IPO since 2021

    Kenvue valued at $41bn after carve-out from US healthcare group

  • Wednesday, 3 May, 2023
    Eli Lilly & Co
    Eli Lilly to seek US approval after Alzheimer’s drug trial success

    Clinical study results could boost patient access to new class of treatment

  • Tuesday, 2 May, 2023
    Pfizer Inc
    Pfizer to start selling stake in Advil maker Haleon within months, says CFO

    US drugmaker adjusts strategy of pursuing deals to replenish drug pipeline

  • Monday, 1 May, 2023
    Noubar Afeyan
    Moderna co-founder calls on US politicians and judges to stop questioning science

    Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases

  • Friday, 28 April, 2023
    Special ReportThe Americas’ Fastest Growing Companies
    Moderna tries to show it’s not a ‘one trick pony’

    Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects

  • Thursday, 27 April, 2023
    Eli Lilly & Co
    Eli Lilly to seek approval of obesity drug that could disrupt weight loss market

    US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth

  • Thursday, 27 April, 2023
    Johnson & Johnson Co Inc
    Talcum powder cancer claims target J&J’s new consumer carve-out

    Executives had tried to shield Kenvue from most of the asbestos lawsuits already facing the group

  • Wednesday, 26 April, 2023
    Medical science
    US regulators approve first human pill derived from faecal matter

    FDA gives green light to C. difficile treatment in boost for microbiome drug developers

  • Friday, 21 April, 2023
    Roe vs Wade
    US Supreme Court pauses restrictions on abortion pill

    Decision halts limitations imposed by a Texas judge earlier this month

  • Wednesday, 19 April, 2023
    Reproductive rights
    US Supreme Court leaves abortion pill ruling on hold

    Justice Samuel Alito extends deadline for further action until Friday

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In